Loading patent…
AssigneesWarsaw Orthopedic, Inc., Medtronic, Inc.
InventorsJohn M. Zanella, Vanja M. King, Christopher M. Hobot, S. Mark Cox, Danielle Biggs, Katara Shaw, William F. McKay, Kathy L. Remsen
Estimating the term…
Effective treatments of pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulindac or a pharmaceutically acceptable salt thereof at or near a target site, one can relieve pain and/or inflammation caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days, at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
An implantable drug depot for reducing, preventing or treating pain and/or inflammation in a patient in need of such treatment, the implantable drug depot comprising sulindac or a pharmaceutically acceptable salt thereof in an amount from about 20 wt. % to about 40 wt. % based on the weight of the drug depot, and at least one biodegradable polymer capable of releasing the sulindac or pharmaceutically acceptable salt thereof for at least 3 days.
An implantable drug depot for reducing, preventing or treating pain and/or inflammation in a patient in need of such treatment, the implantable drug depot comprising sulindac or a pharmaceutically acceptable salt thereof in an amount of from about 20 wt. % to about 40 wt. % of the drug depot, and at least one polymer, wherein the at least one polymer comprises one or more of poly(lactide-co-glycolide), D-lactide, D,L-lactide, L-lactide, D,L-lactide-caprolactone, glycolide-caprolactone, or D,L-lactide-glycolide-caprolactone and said drug depot is capable of releasing the sulindac or pharmaceutically acceptable salt thereof over a period of at least 3 days.
A method for reducing, preventing, or treating pain and/or inflammation, wherein said method comprises implanting a drug depot in a patient in need of such treatment to reduce, prevent or treat pain and/or inflammation, wherein said drug depot comprises sulindac or a pharmaceutically acceptable salt thereof in an amount from about 20 wt. % to about 40 wt. % of the drug depot, and at least one biodegradable polymer and said drug depot is capable or releasing the sulindac or pharmaceutically acceptable salt thereof over at least 3 days.
Dependencies are inferred from the claim text.